NCT06668389View on ClinicalTrials.gov

Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial

PHASE4RecruitingINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

May 12, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Congenital Heart DiseaseRepaired Tetralogy of Fallot (rTOF)Pulmonary RegurgitationSodium-glucose Cotransporter 2 (SGLT2) InhibitorDapagliflozin (Forxiga)

Interventions

DRUG

SGLT2 inhibitor (Dapagliflozin 10mg)

Subjects in SGLT2 inhibitor Group will take dapagliflozin 10mg once daily orally from Visit 1 (Week 1) to Visit 3 (Week 12 ± 1)

Trial Locations (1)

Unknown

RECRUITING

Department of Medicine, Queen Mary Hospital, Hong Kong

All Listed Sponsors

lead

The University of Hong Kong

OTHER